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A rough estimate puts the cell isolation market at approximately $ 6 billion a year worldwide.  One of the key 
commercial technologies uses antibodies conjugated to magnetic micro and nanoparticles (i.e Dynal beads or 
Miltenyi MACS systems).  While clearly effective, whenever antibodies are used, whether conjugated to 
magnetic particles, or fluorescent molecules (such as used in FACS systems), there is always the issue of the 
sensitivity and specificity of the antibody for the targeted cell(s).  This “issue”, amongst others, is the motivator 
for “label free” identification and separation technology.  
 
Removal of human red blood cells, hRBCs, from a blood or bone marrow sample for diagnostic, or therapeutic 
applications is a fundamental laboratory practice/procedure.  While difficult to obtain precise numbers, it has 
been suggested that greater than a billion blood draws are conducted in the US each year.  While for a majority 
of these blood draws an evaluation of the RBCs is an important part, there is still a very large number of tests 
that focus on the remaining blood components after the RBCs have been removed.   While not nearly as 
common as a blood draw, more than 18,000 bone marrow or umbilical cord blood transplants were performed in 
the US in 2013. In the case of bone marrow transplants, the RBCs need to be removed prior to transfusion or 
cryopreservation, regardless of whether the donor and patient’s tissues match.   
 
Viewed from a mechanistic perspective, there are three primary methodologies to remove human RBCs, 
hRBCs, from a blood draw: 1) RBC lysis, 2) immunological based separation in which a RBC is bound with an 
affinity ligand which facilitates RBC removal, or 3) separation of the RBC from the nucleated cells based on 
density differences. The two most commonly used methods are the density difference methods with or without 
hydrophilic polysaccharide addition (e.g Ficoll density gradient based centrifugation, DGC,).   When blood 
samples are only used for further analysis, the condition and the content of the sample after the RBC removal is 
only important with respect to how it affects the subsequent analysis; however, when the RBC depleted sample 
is destined for transfusion into a patient, significantly higher standards are required.   
 
We previously compared RBC removal using the Ficoll-based DGC to lysis protocols.    Using either method 
would remove more than 99% of RBCs; however the average recovery of the spiked cancer cells was 73 and 
89% for the Ficoll and RBC lysis, respectively.   Poor recovery of targeted cells, such as hematopoietic stem 
cells, in the initial RBC depletion step is a problem in the bone marrow transplant/regenerative medicine 
community. In fact, several reports indicate that the recovery of nucleated cells from bone marrow, BMNCs, 
using Ficoll-based DGC, can be as low as 15-30%.  Complementary to these reports, two recent papers 
suggest that cells with high regenerative potential, such as very small embryonic-like stem cells, VSELs and 
mesenchymal stromal cells are depleted with DGC. Finally, there are suggestions that Ficoll DGC can impair 
receptor function of the recovered cells.  
 
It is well established that deoxygenated RBCs are weakly paramagnetic; initially reported by Linus Pauling and 
coworkers in 1936.   Melville and co-workers demonstrated in the mid 1970’s that RBCs can be captured using 
a ferromagnetic wire mesh when the cells are reduced (chemical turned into a state equivalent to the deoxy-
state).  More recently, we have demonstrated that RBCs can be captured in HGMS systems (i.e. Miltenyi Biotec 
MACS columns),  magnetically deposited on slides, deposited on the wall of a channel, and continuous removed 
using a flow through separation system.  While these studies demonstrate theoretically, and experimentally, that 
it is possible to separate RBCs based on intrinsic magnetization, the throughputs in these studies are orders of 
magnitude lower than needed to practically remove RBCs from a typical blood draw.   
In this presentation we will present our latest systems which we suggest can increase the throughputs by orders 
of magnitude which presents the potential for magnetic separation of RBCs to become a practical alternative to 
the currently used approaches.   
